These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. A pilot phase II study of alternate day ganciclovir and foscarnet in preventing cytomegalovirus (CMV) infections in at-risk pediatric and adolescent allogeneic stem cell transplant recipients. Shereck EB; Cooney E; van de Ven C; Della-Lotta P; Cairo MS Pediatr Blood Cancer; 2007 Sep; 49(3):306-12. PubMed ID: 16972242 [TBL] [Abstract][Full Text] [Related]
5. Foscarnet prophylaxis of cytomegalovirus infections in patients undergoing allogeneic bone marrow transplantation (BMT): a dose-finding study. Bregante S; Bertilson S; Tedone E; Van Lint MT; Trespi G; Mordini N; Berisso G; Gualandi F; Lamparelli T; Figari O; Benvenuto F; Raiola AM; Bacigalupo A Bone Marrow Transplant; 2000 Jul; 26(1):23-9. PubMed ID: 10918402 [TBL] [Abstract][Full Text] [Related]
6. CMV-antigenemia after allogeneic bone marrow transplantation: correlation of CMV-antigen positive cell numbers with transplant-related mortality. Bacigalupo A; Tedone E; Isaza A; Soracco M; Van Lint MT; Sanna A; Frassoni F; Occhini D; Gualandi F; Lamparelli T Bone Marrow Transplant; 1995 Jul; 16(1):155-61. PubMed ID: 7581116 [TBL] [Abstract][Full Text] [Related]
7. High-dose acyclovir and pre-emptive ganciclovir in prevention of cytomegalovirus disease in pediatric patients following peripheral blood stem cell transplantation. Hazar V; Kansoy S; Küpesiz A; Aksoylar S; Kantar M; Yeşilipek A Bone Marrow Transplant; 2004 May; 33(9):931-5. PubMed ID: 15034541 [TBL] [Abstract][Full Text] [Related]
8. Early treatment of CMV infections in allogeneic bone marrow transplant recipients with foscarnet or ganciclovir. Bacigalupo A; van Lint MT; Tedone E; Moro F; Sanna MA; Longren M; Trespi G; Frassoni F; Occhini D; Gualandi F Bone Marrow Transplant; 1994 Jun; 13(6):753-8. PubMed ID: 7920310 [TBL] [Abstract][Full Text] [Related]
9. Randomized clinical trial of ganciclovir vs acyclovir for prevention of cytomegalovirus antigenemia after allogeneic transplantation. Burns LJ; Miller W; Kandaswamy C; DeFor TE; MacMillan ML; Van Burik JA; Weisdorf DJ Bone Marrow Transplant; 2002 Dec; 30(12):945-51. PubMed ID: 12476289 [TBL] [Abstract][Full Text] [Related]
10. Pre-emptive therapy against cytomegalovirus (CMV) disease guided by CMV antigenemia assay after allogeneic hematopoietic stem cell transplantation: a single-center experience in Japan. Kanda Y; Mineishi S; Saito T; Seo S; Saito A; Suenaga K; Ohnishi M; Niiya H; Nakai K; Takeuchi T; Kawahigashi N; Shoji N; Ogasawara T; Tanosaki R; Kobayashi Y; Tobinai K; Kami M; Mori S; Suzuki R; Kunitoh H; Takaue Y Bone Marrow Transplant; 2001 Feb; 27(4):437-44. PubMed ID: 11313674 [TBL] [Abstract][Full Text] [Related]
11. Cytomegalovirus antigenemia and outcome of patients treated with pre-emptive ganciclovir: retrospective analysis of 241 consecutive patients undergoing allogeneic hematopoietic stem cell transplantation. Yanada M; Yamamoto K; Emi N; Naoe T; Suzuki R; Taji H; Iida H; Shimokawa T; Kohno A; Mizuta S; Maruyama F; Wakita A; Kitaori K; Yano K; Hamaguchi M; Hamajima N; Morishima Y; Kodera Y; Sao H; Morishita Y Bone Marrow Transplant; 2003 Oct; 32(8):801-7. PubMed ID: 14520425 [TBL] [Abstract][Full Text] [Related]
12. Cytomegalovirus pp65 antigenemia-guided pre-emptive treatment with ganciclovir after allogeneic stem transplantation: a single-center experience. Manteiga R; Martino R; Sureda A; Labeaga R; Brunet S; Sierra J; Rabella N Bone Marrow Transplant; 1998 Nov; 22(9):899-904. PubMed ID: 9827819 [TBL] [Abstract][Full Text] [Related]
13. Cytomegalovirus antigenemia and outcomes of patients undergoing allogeneic peripheral blood stem cell transplantation: effects of long-term high-dose acyclovir prophylaxis and preemptive ganciclovir treatment. Hazar V; Ugur A; Colak D; Saba R; Tezcan G; Kupesiz A; Karadogan I; Gultekin M; Yesilipek A; Undar L Jpn J Infect Dis; 2006 Aug; 59(4):216-21. PubMed ID: 16936338 [TBL] [Abstract][Full Text] [Related]
14. Valacyclovir for the prevention of cytomegalovirus infection after allogeneic stem cell transplantation: a single institution retrospective cohort analysis. Vusirikala M; Wolff SN; Stein RS; Brandt SJ; Morgan DS; Greer JP; Schuening FG; Dummer JS; Goodman SA Bone Marrow Transplant; 2001 Aug; 28(3):265-70. PubMed ID: 11535994 [TBL] [Abstract][Full Text] [Related]
15. A randomised trial comparing cytomegalovirus antigenemia assay vs screening bronchoscopy for the early detection and prevention of disease in allogeneic bone marrow and peripheral blood stem cell transplant recipients. Humar A; Lipton J; Welsh S; Moussa G; Messner H; Mazzulli T Bone Marrow Transplant; 2001 Sep; 28(5):485-90. PubMed ID: 11593322 [TBL] [Abstract][Full Text] [Related]